By: GO Therapeutics

04 OctGO Therapeutics appoints Dr. Robert J. Wills to Board of Directors


Cambridge, MA, October 4, 2017 – GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer…

Read More

25 SepSalubris Pharmaceuticals Invests $5 Million in GO Therapeutics


Strategic investment to help accelerate antibody development programs against novel solid tumor targets Cambridge, MA, September 25, 2017 –GO Therapeutics today…

Read More